Scientific publications

Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8 + T cells

Jul 1, 2017 | Magazine: Nature Communications

Michel Enamorado  1 , Salvador Iborra  1 , Elena Priego  1   2 , Francisco J Cueto  1   2 , Juan A Quintana  1 , Sarai Martínez-Cano  1 , Ernesto Mejías-Pérez  3 , Mariano Esteban  3 , Ignacio Melero  4   5 , Andrés Hidalgo  1   6 , David Sancho  1


The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8+ T cells with a resident memory (Trm) phenotype correlates with improved survival.

However, the interplay of circulating CD8+ T cells and Trm cells remains poorly explored in tumour immunity. Using different vaccination strategies that fine-tune the generation of Trm cells or circulating memory T cells, here we show that, while both subsets are sufficient for anti-tumour immunity, the presence of Trm cells improves anti-tumour efficacy.

Transferred central memory T cells (Tcm) generate Trm cells following viral infection or tumour challenge. Anti-PD-1 treatment promotes infiltration of transferred Tcm cells within tumours, improving anti-tumour immunity. Moreover, Batf3-dependent dendritic cells are essential for reactivation of circulating memory anti-tumour response.

Our findings show the plasticity, collaboration and requirements for reactivation of memory CD8+ T cells subsets needed for optimal tumour vaccination and immunotherapy.

CITA DEL ARTÍCULO  Nat Commun. 2017 Jul 17;8:16073.  doi: 10.1038/ncomms16073